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Introduction: Metabolic disorders are common amongst HIV-infected patients. Data from
real-life setting on the impact of DTG/ABC/3TC in virologically suppressed HIV-infected
patients are scarce.
Methods: We investigated the modiﬁcation of metabolic proﬁle including fasting glucose,
lipid proﬁle and markers of insulin resistance (IR) in experienced patients switching from
a boosted protease inhibitors (bPI) or a non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based regimen to DTG/ABC/3TC in a prospective, observational, multicenter
study.
Results: We enrolled 131 HIV-infected patients, of whom 91 (69.5%) males, mean age was
50.5±10.6 years. CDC stage was A in 66 (50.4%) patients, of whom 91 (69.5%) had acquired
HIV through sexual contacts. The previous regimen was bPI-based in 79 patients (60.3%)
and NNRTI-based in 52 (39.7%). Patients switching from NNRTI showed a signiﬁcant
reduction at week 24 in total cholesterol (TC) and low-density lipoprotein cholesterol
(LDL). Triglycerides/high-density lipoprotein cholesterol (TG/HDL) ratio, HDL, median
TG and TG/HDL ratio did not show signiﬁcant modiﬁcation during follow-up times.
Among patients switching from a bPI, we observed a signiﬁcant reduction in TC and LDL
at both follow-up times and a slight increase in HDL. Triglycerides/HDL ratio, median TG
and TG/HDL ratio showed a decrease over time that became signiﬁcant at weeks 24 and 48.
Blood glucose levels did not signiﬁcantly vary during the observation period in patients
switching from both bPI and NNRTI-based regimens.
Conclusion: Our data suggest an improvement in lipid proﬁle and TG/HDL ratio in
pretreated HIV-1-infected patients who switched to DTG/ABC/3TC over 48 weeks, espe-
cially in those previously receiving a bPI-based regimen.
Keywords: HIV-1 infection, dolutegravir/abacavir/lamivudine, lipid proﬁle
Introduction
Metabolic disorders are common amongst HIV-infected patients and show a higher
prevalence in respect to healthy controls.1,2 The proportion of HIV-infected adults over
the age of 50 is also growing, thus increasing the number of HIV-infected people at
particular risk for metabolic perturbations and cardiovascular disease.3 Considering
long-term use of antiretroviral therapy, the impact on the lipid proﬁle of antiretroviral
agents is critical when choosing from among different options for a treatment regimen.
Dolutegravir (DTG), a second-generation unboosted integrase inhibitor with
a high barrier to resistance, proved efﬁcacious and safe in naïve and experienced
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patients in clinical trials and is currently recommended by
guidelines both for initial therapy and for optimization
strategy.4
In the STRIVING study, switching to the combination of
DTG with abacavir/lamivudine (ABC/3TC) as single tablet
regimen versus continuing current combination antiretroviral
therapy (cART) demonstrated noninferiority,5 good tolerabil-
ity and improvements in inﬂammatory biomarker proﬁles.6
More recently, the study NEAT 022 showed that switching to
DTG +2 nucleoside reverse transcriptase inhibitors (NRTI)
compared to staying on a boosted protease inhibitor (bPI)-
based regimen in HIV patients with high cardiovascular risk
and/or age >50 years was associated with a signiﬁcant
improvement in lipid proﬁle.7
To date, real-life data on the impact of DTG/ABC/3TC in
virologically suppressed HIV-infected patients are limited.
We aimed at evaluating the modiﬁcation of metabolic
proﬁle including fasting glucose, lipid proﬁle and markers
of insulin resistance (IR) in experienced patients switching
from a bPI or a non-nucleoside reverse transcriptase inhi-
bitor (NNRTI)-based regimen.
Methods
The SCOLTA Project (Surveillance Cohort Long-Term
Toxicity of Antiretrovirals) is a prospective, observational,
multicenter study created to assess the incidence of
adverse events in patients receiving new antiretroviral
drugs in clinical practice. This on-line pharmacovigilance
program currently involves 21 Italian infectious disease
departments. The Project has an internet site (http://www.
cisai.info) where grade III and IVadverse events according
to DAIDS table are recorded (http://rcc.tech-res-intl.com/
tox_tables.htm). The SCOLTA Project currently includes 4
cohorts: dolutegravir, darunavir/cobicistat, atazanavir/
cobicistat and tenofovir alafenamide/emtricitabine/elvite-
gravir/cobicistat. All patients starting one of the drugs
included in the surveillance program in participating cen-
ters are consecutively asked to participate in the study
after signing a written informed consent. Patients undergo
follow-up at 6-month intervals and adverse events are
notiﬁed when they are clinically observed. Complete data
collection and follow-up procedures for the cohorts are
described elsewhere.8
For the present study, we included all patients who
switched to DTG/ABC/3TC from a triple cART based on
a bPI or a NNRTI, had HIV RNA<50 copies/mL at enrolment
and had at least 1 follow-up visit or reported reasons for
interruption before the ﬁrst follow-up visit. We aimed at
evaluating the potential beneﬁt of switching to DTG/ABC/
3TC from different regimens on cardiovascular risk.
Speciﬁcally, we describe the changes in fasting glucose,
lipid proﬁle and insulin resistance, evaluated as triglycerides/
high-density lipoprotein cholesterol (TG/HDL) ratio over 48
weeks after initiating DTG/ABC/3TC in HIV-infected indi-
viduals switching from bPI and NNRTI. Triglycerides/HDL
ratio has been demonstrated to be a strong predictor of IR and
cardiovascular events in several studies.9–11 Lipid proﬁle
included total cholesterol (TC), HDL and TG.
Statistical analysis
Categorical and discrete variables were described as fre-
quency and percentage (%). Continuous variables were
described using mean and SD if normally distributed,
and median and interquartile range (IQR) if not normally
distributed. At univariate analysis, groups were compared
using chi-square for categorical variables and analysis of
variance for continuous variables, or via a nonparametric
test (Mann–Withney U test) for non-normally distributed
continuous variables. Repeated measures were analyzed as
change from baseline; to evaluate if means were signiﬁ-
cantly different from zero, within groups, AND we used
the Student's t-test for normally distributed and the signed
rank test for not normally distributed differences from
baseline (ie TG/HDL).
Ethical approval
The study has been approved by the Ethics committee of
the coordinator (Luigi Sacco Hospital Ethics Committee,
June 13, 2013, registry number 352) and of the participat-
ing centers.
Results
Out of 611 patients enrolled from July 2014 to July 2017,
131 HIV-infected patients met the criteria of inclusion for
this analysis.
The median follow-up time was 11 (IQR 7-19) months;
91 (69.5%) were males and 91 (69.5%) had acquired HIV
through sexual contacts. CDC stage was A in 66 (50.4%)
patients. Mean age at enrolment was 50.5±10.6 years and
mean CD4-T cell count 640±357 cell/μL. Thirty (29.1%)
patients had detectable HCV antibodies (17 of whom were
HCV-RNA positive) and 8 (6.2%) were diabetic. The
previous regimen was bPI-based in 79 patients (60.3%)
and NNRTI-based in 52 (39.7%). Thirteen patients were
on statins at study entry (8 in NNRTI and 5 in bPI group),
which were continued in all cases, and no patient started
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such a treatment during follow-up. Out of the 131 patients,
5 (3.8%) did not report any lipid variables at study entry
and were excluded from the analysis of lipids, but included
in the analysis of blood glucose. Out of the 126 remaining
subjects, 120 had the complete lipid proﬁle but 6 lacked at
least 1 variable. Overall, lipid analysis was based on 126,
106 and 72 patients at baseline, week 24 and week 48,
respectively.
The patients who switched from a NNRTI-based regi-
men showed lower baseline TC and TG and higher HDL
levels than those who switched from bPI. Furthermore,
TG/HDL ratio was higher in patients who switched from
a bPI regimen (median 3.6, IQR 1.6-6.2 vs 1.9, 1.2-2.6,
p<0.0001). The baseline characteristics of the study popu-
lation are further described in Table 1.
During follow-up, patients switching from NNRTI
showed a reduction in TC that was signiﬁcant at week 24
(−11.3±29.6 mg/dL, p=0.02 at 24 and −2.3±26.0 mg/dL at 48
weeks, p=0.65); LDL showed the same trend (−12.2
±28.3 mg/dl at week 24, p=0.01 and −1.3±34.6 mg/dL at
week 48, p=0.85). A slight nonsigniﬁcant reduction in HDL
at week 24 and 48 (−1.6±9.4 mg/dL, p=0.31 and −2.1±9.5,
p=0.30, respectively) was also observed. No signiﬁcant
changes were observed in TC/HDL ratio during follow-up
(0.01±0.91, p=0.92, 0.12±0.61, p=0.33). Median TG levels
remained stable during observation: 104 mg/dL at baseline
(IQR 76-121) and 24 weeks (IQR 65-139) and 106 mg/dL at
48 weeks (IQR 78 −168). Mean changes from baseline were
not signiﬁcantly different from 0 at both follow-up visits
(p=0.65 and 0.83, respectively). TG/HDL ratio did not
show signiﬁcant modiﬁcation during follow-up times: 0.00
(IQR −0.47-0.51), p=0.51, at week 24 and 0.11 (IQR −0.19-
0.74), p=0.33, at week 48 (Figure 1).
Among patients switching from a bPI, we observed
a signiﬁcant reduction in TC and LDL at both weeks 24
(−9.1±29.8 mg/dL, p=0.015 and −18.7±31.6 mg/dL,
p<0.0001, respectively) and 48 (−11.2±33.5 mg/dL, p=0.026
and −22.0±35.1 mg/dL, p=0.0001, respectively) and a slight
increase in HDL (1.6±8.9 mg/dL, p=0.15, 2.4±9.8 mg/dL,
p=0.10). TC/HDL ratio decreased signiﬁcantly at weeks 24
and 48 (−0.41±1.34, p=0.02, −0.59±1.21 p=0.002). Median
TG signiﬁcantly declined over time as follows: 149 (IQR 95-
215) mg/dL at baseline, 122 mg/dL (IQR 75-178) at 24
(p=0.0006) and 118 mg/dL (IQR 83-141) at 48 weeks
(p=0.015). TG/HDL ratio showed a decrease over time that
became signiﬁcant at weeks 24 and 48 (−0.49, IQR −1.97-
0.11, p=0.0003 and −0.89 IQR −1.75-0.00, p<0.0001, respec-
tively) (Figure 1).
In both groups, the decrease was more marked in
patients who started with higher levels of blood lipids.
Despite the small sample size, in subjects with
TC>240 mg/dL at baseline and not on statins, we found
that TC levels signiﬁcantly decreased at T1: −26.0±4.7
(p<0.0001) and −35.0±10.5 (p=0.008) mg/dL in those
switching from bPI and NNRTI, respectively.
Blood glucose levels did not signiﬁcantly vary during
the observation period in patients switching from both
bPI and NNRTI-based regimens: excluding 8 diabetic
subjects (4 in each group), at weeks 24 and 48, variations
were 1.2±1.6 and 1.2±62.1 mg/dL for bPI patients, and
0.8±5.7 and −2.0±7.0 mg/dL for NNRTI.
Two cases in each group that were undetectable at
week 24 and had a detectable viral load at week 48.
Discussion
The results of our study obtained in a “real-world” sce-
nario are in part original and in part conﬁrmatory.
Our data conﬁrm in clinical practice that switching from
a bPI to DTG/ABC/3TC in experienced HIV-infected
patients with undetectable viral load is associated with an
overall improvement of lipid proﬁle. We also found beneﬁ-
cial effects on TG/HDL ratio, a marker of insulin resistance,
glucose homeostasis and cardiovascular risk.
Both patients switching from bPI and NNRTI to DTG/
ABC/3TC showed a decrease over time in TC levels,
a primary target of lipid-lowering therapies. However, levels
of HDL did not markedly change during follow-up time.
Furthermore, patients switched from bPI showed
a signiﬁcant reduction in TC/HDL ratio, thus suggesting
a potential reduction in the risk of cardiovascular disease.
With respect to hypertriglyceridemia, which is also
considered an independent risk factor for cardiovascular
disease,12 individuals treated with DTG/ABC/3TC showed
an overall decrease, that resulted statistically signiﬁcant in
patients switching from bPI at every follow-up evaluation.
DTG/ABC/3TC demonstrated a neutral effect on gly-
cemia in both treatment groups.
One of the most interesting ﬁndings of our study was
the beneﬁcial effect on the TG/HDL ratio recognized as
a strong predictor of insulin resistance and cardiovascular
disease in patients switching from bPI.1,2
Boosted PIs (Darunavir) and Efavirenz have been asso-
ciated with a worse impact on lipids compared to
Dolutegravir (Single and Flamingo) in antiretroviral
naïve patients.13,14 Furthermore, switching to DTG from
a boosted PI in the NEAT 022 study compared to staying
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Table 1 Baseline characteristics of patients starting dolutegravir/abacavir/lamivudine after switching from a boosted protease inhibitor
(bPI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI)
Previous NNRTI, N=52 (39.7%) Previous bPI, N=79 (60.3%)
N or mean or
median
% or SD or
IQR
N or mean or
median
% or SD or
IQR
Female gender * 14 26.9 26 32.9
Age (years) (mean, SD)** 51.3 12.1 49.9 9.7
Ethnicity Caucasian* 50 96.2 75 94.9
HIV transmission category*
IVDU
Homo/heterosexual
Other or unknown
3
41
8
5.8
78.8
15.4
13
50
16
16.5
53.3
20.2
CDC stage*
A
B
C
29
17
6
55.8
32.7
11.5
37
21
21
46.8
26.6
26.6
CD4 count (cells/μL)*
<200
200–349
≥350
0
12
40
0
23.1
76.9
13
24
42
16.5
30.4
53.2
Previous regimen (NNRTI)*
EFV
RPV
ETV
NVP
34
9
4
5
65.4
17.3
7.7
9.6
–
–
–
–
–
–
–
–
Previous regimen (bPI)*
ATV
DRV
LPV
FAMP
SQV
–
–
–
–
–
35
33
7
3
1
44.3
41.8
8.9
3.8
1.27
Anti- HCV antibodies positive*
Detectable HCV-RNA*
5
4
9.8
7.7
25
13
32.5
16.5
Median time in follow-up***(months) 9 6–12 13 7–24
Statins therapy* 8 15.4 5 6.3
Diabetes* 4 7.7 4 5.1
Total cholesterol (TC, mg/dL)** 198 43 212 46
High-density lipoprotein (HDL, mg/dL)- C** 58 22 48 16
Low-density lipoprotein (LDL, mg/dL)-C** 118 39 144 46
Triglycerides (TG, mg/dL)*** 104 76–121 149 95–215
TG/HDL ratio*** 1.9 1.2–2.6 3.6 1.6–6.2
TC/HDL ratio*** 3.5 2.8–4.4 4.5 3.5–5.7
Notes: *Data expressed as number and percentage (%). **Data expressed as mean and standard deviation (SD). ***Data expressed as median and interquartile range (IQR).
Abbreviations: EFV, Efavirenz; RPV, Rilpivirine; ETV, Etravirine; NVP, Nevirapine; ATV, Atazanavir, DRV, Darunavir; LPV, Lopinavir; FAMP, Fosamprenavir; SQV, Saquinavir; TG,
triglycerides; bPI, Boosted Protease Inhibitors.
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on a bPI-based regimen was associated with a signiﬁcant
improvement in lipid proﬁle. Therefore, our data conﬁrm
in an observational “real-life” study that switching to
DTG/ABC/3TC could be associated with an improvement
of lipids and markers of insulin resistance such as TG/
HDL ratio. In our opinion, the discontinuation of the
previous “third drug” (NNRTI or bPI) could explain
these results since Dolutegravir has proved neutral on
metabolic parameters.15
According to our data, patients switching from bPI
showed a high TG/HDL ratio suggestive of insulin resis-
tance at baseline.9,16,17 However, it is well known that there
is variability in the threshold to deﬁne insulin resistance
using TG/HDL ratio based on age, gender and ethnicity.18
The signiﬁcant and persistent TG/HDL ratio decrease regis-
tered in our study at both follow-up times suggests that
patients at increased risk of developing abnormal glucose
tolerance and cardiovascular disease could beneﬁt, in term
of TG/HDL ratio, by the switch to DTG/ABC/3TC.
However, patients switching from NNRTI, who pre-
sented a normal mean TG/HDL ratio at baseline, did not
show signiﬁcant modiﬁcations during follow-up.
Therefore, the beneﬁt with regard to TG/HDL ratio
seems lower in these patients.
The present study has some limitations. Firstly, the
sample size was small, with only 131 patients enrolled
with a limited observation period. Secondly, despite the
prospective data collection, the study was purely observa-
tional. We do not have a randomized control group and
cannot demonstrate the causality between ART switch and
the measured outcomes. Thirdly, lifestyle interventions
during follow-up have not been registered, and thus we
cannot estimate their impact on the study outcomes. Thus,
it is possible that the choice to switch regimens was guided
by different patients’ characteristics that may have inﬂu-
enced the results of the analysis, and this may introduce
a confounder in the analysis.
However, as far as we know, this is the ﬁrst observa-
tional study to evaluate the impact on metabolic proﬁle of
switching patients with an undetectable viral load to DTG/
ABC/3TC in an unselected “real-life” population.
Therefore, our study adds new and more generalizable
evidence to the existing knowledge deriving only from
randomized clinical trials.
Taken together, our data suggest an improvement in
lipid and metabolic proﬁle in cART-treated patients
switched to DTG/ABC/3TC over 48 weeks, especially in
those previously receiving a bPI-based regimen.
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Figure 1 Changes from baseline to 24 (T1) and 48 (T2) weeks in total cholesterol (TC), high-density lipoprotein (HDL), TC/HDL ratio, low-density lipoprotein (LDL),
triglycerides (TG) and TG/HDL ratio. Data are shown as a mean change from baseline for TC, HDL, TC/HDL, LDL, TG and median change from baseline for TG/HDL.
Abbreviations: bPI, boosted protease Inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors.
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